Right to Try Law Fails Patients Despite FDA Rejection of RP1 Melanoma Therapy
The FDA’s rejection of RP1, an experimental melanoma treatment, highlights the limitations of the 2018 Right to Try Act. Despite its promise to grant...
The FDA’s rejection of RP1, an experimental melanoma treatment, highlights the limitations of the 2018 Right to Try Act. Despite its promise to grant...
The FDA has rejected Replimune’s melanoma treatment RP1, a drug doctors say could save lives. Robert F. Kennedy Jr. denies involvement, blaming FDA Co...